Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Malaria transmission blocking compounds: a patent review46
FAK inhibitors in cancer, a patent review – an update on progress36
Update on mGlu4 modulator patents: 2017 to present35
Recent developments of agents targeting Vibrio cholerae : patents and literature data35
The role of patent analysis in target selection34
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)33
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature31
Caspase inhibitors: a review on recently patented compounds (2016–2023)29
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)29
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities29
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)27
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review26
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)25
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present24
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)24
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
PDE1 inhibitors: a review of the recent patent literature (2008-present)22
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
An updated patent review of AKT inhibitors (2020 – present)22
A patent review of MAPK inhibitors (2018 – present)22
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)21
Antiprotozoal drugs: challenges and opportunities21
Inhibition of GTPase KRAS G12D : a review of patent literature21
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)19
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)19
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)18
Small-molecule RNA ligands: a patent review (2018–2024)18
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)18
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)17
An updated patent review of MALT1 inhibitors (2021–present)16
An updated patent review on PD-1/PD-L1 antagonists (2022-present)16
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
Antimalarial drugs: what’s new in the patents?15
A patent review of IDH1 inhibitors (2018-present)15
Biofilm and bacterial membrane vesicles: recent advances14
A patent and literature review of CDK12 inhibitors14
Dopamine D3 receptor ligands: a patent review (2014–2020)14
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
A patent review of NLRP3 inhibitors to treat autoimmune diseases13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)13
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
An updated patent review of EZH2 inhibitors (2024–present)12
Are patents important indicators of innovation for Chagas disease treatment?12
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)11
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
An updated patent review of TRPA1 antagonists (2020 – present)11
Correction11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)11
The patent review of the biological activity of tropane containing compounds11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress10
A patent review of BRD4 inhibitors (2020–present)10
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
A patent review of selective CDK9 inhibitors in treating cancer10
Patent landscape of small molecule inhibitors of METTL3 (2020-present)9
Rho kinase inhibitors: a patent review (2017–2023)9
A patent review of CXCR7 modulators (2019-present)9
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)9
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)9
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)9
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)8
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)8
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)8
A patent perspective of antiangiogenic agents8
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published8
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update7
Recent advances in the development of STING inhibitors: an updated patent review7
An updated patent review on monoamine oxidase (MAO) inhibitors7
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)7
A patent review of glutaminyl cyclase inhibitors (2004–present)7
Therapeutic cysteine protease inhibitors: a patent review (2018–present)7
Nurr1 modulators – a patent review (2019–present)7
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)7
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents7
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid7
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20236
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)6
A patent review of xanthine oxidase inhibitors (2021–present)6
An updated patent review of stimulator of interferon genes agonists (2021 – present)6
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective6
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)6
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)6
A review of the patent literature surrounding TRPV1 modulators6
Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 20216
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)6
An updated patent review of Mcl-1 inhibitors (2020–2022)6
Pitfalls in patenting academic CAR-T cells therapy6
Proteasome inhibitors as anticancer agents5
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present5
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)5
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)5
BET inhibitors: an updated patent review (2018–2021)5
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)5
An updated patent review of BRD4 degraders5
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)5
Recent updates on Wnt signaling modulators: a patent review (2014-2020)5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
An updated patent review of glutaminase inhibitors (2019–2022)5
Anticancer drugs: where are we now?5
Natural products as a source of new anticancer chemotypes5
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)5
A patent review of adenosine A2Breceptor antagonists (2016-present)5
A patent review of IDO1 inhibitors for cancer (2023 – present): an update5
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature5
CBL-B – An upcoming immune-oncology target4
Update on JNK inhibitor patents: 2015 to present4
Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)4
Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)4
An updated patent review of SOS1 inhibitors (2022–present)4
MEK inhibitors in oncology: a patent review and update (2016 – present)4
CDC7 kinase inhibitors: a survey of recent patent literature (2017–2022)4
Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021–2024)4
PIM kinase inhibitors: an updated patent review (2016-present)4
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)4
Malaria vaccines4
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective4
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review4
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)4
Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)4
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections4
Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)4
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present)4
Targeting the TGF-β signaling pathway: an updated patent review (2021–present)4
0.04085111618042